Corneal Crosslinking for Treatment of Corneal Neovascularization

Last updated: July 23, 2024
Sponsor: Price Vision Group
Overall Status: Active - Recruiting

Phase

2/3

Condition

N/A

Treatment

30 minute photoactivation of riboflavin 0.1%

10 minute photoactivation of riboflavin 0.1%

Clinical Study ID

NCT04787471
2021-001
  • Ages > 18
  • All Genders

Study Summary

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 years of age or older

  • With active inflammation or infection causing vascularization and possibly meltingof the cornea, or vessels extending into the cornea causing lipid deposition, orvascularization that could significantly increase the risk of rejection of a currentor planned corneal transplant, or vessels that continue to extend into the corneadespite topical treatment with corticosteroids.

  • Signed written informed consent.

Exclusion

Exclusion Criteria:

  • Known sensitivity to treatment medications

  • Current condition that in the investigator's opinion could compromise safety or dataintegrity.

  • Pregnancy (including plan to become pregnant) or lactation during the course of thestudy

Study Design

Total Participants: 62
Treatment Group(s): 2
Primary Treatment: 30 minute photoactivation of riboflavin 0.1%
Phase: 2/3
Study Start date:
May 03, 2021
Estimated Completion Date:
September 15, 2025

Connect with a study center

  • Price Vision Group

    Indianapolis, Indiana 46260
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.